Hey there

CCO Independent Conference Coverage

2005 Annual Meeting of the American Association for the Study of Liver Diseases*

November 11-15, 2005 | San Francisco, CA

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Latest Findings in HBV Management

Track 1 of 4

Faculty:
		Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Robert G. Gish, MD Emmet B. Keeffe, MD, MACP
		Robert P. Perrillo, MD

HCV Management: Facing New Challenges

Track 2 of 4

Faculty:
		Gary L. Davis, MD Jean-Michel Pawlotsky, MD, PhD Mitchell L. Shiffman, MD

Addressing Side Effects and Coinfections

Track 3 of 4

Capsule Summaries

Expert Analysis

Faculty:
		Nezam H. Afdhal, MD, FRCPI Raymond T. Chung, MD Mark S. Sulkowski, MD

Managing HCC and Liver Transplantation

Track 4 of 4

Capsule Summaries

Expert Analysis

Faculty:
		Norah Terrault, MD, MPH Paul Martin, MD Robert J. Fontana, MD

Expert Highlights (mp3)

Listen to the experts quickly summarize the most important data from the conference!

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged onto the clinicaloptions.com site to listen to or download the mp3 files.

	Robert G. Gish, MD, provides an overview of the data from key studies in HBV presented at the conference. (4 minutes)		Download Audio
	Mitchell L. Shiffman, MD, reviews the latest antiviral therapies, and high-dose treatment strategies for the management of HCV infection. (2 minutes)		Download Audio
	Raymond T. Chung, MD, discusses the issue of acute HCV infection in HIV-infected patients. (5 minutes)		Download Audio
	Mark S. Sulkowski, MD, discusses the effects of interferon treatment on fibrosis in HCV/HIV coinfected patients. (2 minutes)		Download Audio

CCO Daily News (Not required for CME credit)

November 15, 2005

November 14, 2005

November 13, 2005

Hepatitis C continues following a benign course in long-term follow-up of the untreated Irish women cohort with iatrogenic infection

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

CAPSULE SUMMARY:

Optimizing Ribavirin Dose by Patient Weight Enhances Sustained Viral Responses in Patients With Chronic Hepatitis C

Sustained viral response rates were superior with weight-based dosing of ribavirin compared with fixed-dose ribavirin, especially in HCV genotype 1 patients with high viral load, according to data from the WIN-R study.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES